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ABSTRACT
Although Parkinson’s disease (PD) is classically considered to be a motor 
system disease, subtle cognitive impairments can be observed even during 
the early phases of PD. In this article we review behavioral and neurochemi-
cal studies on the cognitive alterations observed in rats treated with intranigral 
infusion of the neurotoxin MPTP. The critical role of dopamine release in the 
dorsal striatum and its modulation by adenosine receptors is also reviewed 
as a potential strategy to treat the cognitive disabilities of PD patients who do 
not improve with levodopa therapy. Most of the impairments presented by rats 
treated with intranigral infusion of MPTP are similar to those observed during 
the early phase of PD, when a moderate loss of nigral dopamine neurons 
(40-70%) results in sensory and memory defi cits with no major motor impair-
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ments. These animals also model the working memory and habit learning 
defi cits, with long-term spatial (episodic) memories being mostly spared as 
observed in non-demented PD patients. The intranigral infusion of MPTP in 
rats has led to the development of useful models, which do not present gross 
motor impairments that would otherwise compromise the interpretation of the 
performance of the animals in cognitive tasks. 
Keywords: Parkinson’s disease, learning, memory, cognition, MPTP, rats, 
animal model.
RESUMEN
Aunque el mal de Parkinson (DP) es considerado clásicamente como un 
desorden del sistema motor, pueden observarse ligeros deterioros cognitivos 
aun en las fases iniciales del DP. En este artículo revisamos estudios conduc-
tuales y neuroquímicos sobre alteraciones cognitivas observadas en ratas 
tratadas con infusiones intranigrales de la neurotoxina MPTP. El papel crítico 
de la liberación de dopamina en el estriado dorsal y su modulación por los 
receptores de adenosina también es revisada como una estrategia potencial 
para tratar los deterioros cognitivos en pacientes con desorden de Parkinson 
(PD) que no mejoran con la terapia de levo dopa. Resultados: La mayoría 
de de los daños presentados en ratas con infusiones intranigrales de MPTP 
son similares a los observados en las primeras fases de PD, una pérdida 
moderada de neuronas nigrales dopaminérgicas (40-70%) que causa défi -
cits sensoriales y motores y poco deterioro motor. Estos animales también 
modelan los défi cits de memoria de trabajo y aprendizaje de hábitos, con la 
memoria de largo plazo espacial (episódica) mayormente preservada como 
se observa en los pacientes sin DP. La infusión intranigral de MPTP en ratas 
a llevado al desarrollo de modelos útiles, ya que no presentan un deterioro 
motor excesivo que podría de otra manera comprometer la interpretación de 
de la ejecución de los animales en tareas cognitivas.
Palabras clave: mal de Parkinson, aprendizaje, memoria, cognición, 
MPTP, ratas, modelo animal.
Parkinson’s disease (PD) is the second most common neurodegenerative 
disorder, following Alzheimer’s disease, affecting approximately 1% of the 
population older than 50 years (Duvoisin 1991). Current estimates from the 
American Parkinson’s Disease Foundation put the number of American citi-
zens suffering from this disease at more than 1.5 million individuals. Since the 
incidence of the disease increases with age (the most important risk factor), 
it is likely that the number of people suffering from PD will rise as improved 
health care lengthens the average life span. 
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Classically, PD is considered to be a motor system disease and its diag-
nosis is based on the presence of a set of cardinal motor signs (e.g. rigidity, 
bradykinesia, rest tremor and postural refl ex disturbance). These symptoms 
of PD mainly result from the progressive degeneration of dopamine neurons 
of the substantia nigra pars compacta (SNc) that project predominantly to the 
striatum (Hirsch et al. 1988), a fact that contributes to the prevailing view that 
the basal ganglia are mainly concerned with motor control functions (Heikkila 
et al. 1989). More recently, an increasing amount of evidence has suggested 
that this system is also critically involved in learning and memory processes 
(Brown et al. 1997), as indicated by the fact that many cognitive impairments, 
including memory defi cits, occur during the early stage of PD even before the 
development of its classical symptoms (Dubois and Pillon 1997; Owen et al. 
1995). The non-motor symptoms that include cognitive defi cits can be more 
important than the motor defi cits to determine the patients’ quality of life and 
represent an important factor to determine the need for nursing home care. 
On the other hand, animal models are an invaluable tool for studying the 
pathogenesis and progression of human diseases, as well as for testing new 
therapeutic intervention strategies. PD is one of many human diseases which 
do not appear to have arisen spontaneously in animals. The characteristic 
features of the disease can, however, be more or less faithfully mimicked in 
animals through genetic approaches and the administration of various neuro-
toxic agents that interfere with dopaminergic neurotransmission. Despite the 
recent discovery of mutations in the alpha-synuclein gene (and some other 
genes) in a few PD patients that has led to the development of gene-based 
PD models (von Bohlen und Halbach et al. 2004), the administration of differ-
ent neurotoxins such as 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phe-
nyl-1,2,3,6,-tetrahydropyridine (MPTP), which disrupt or destroy the dopami-
nergic system, remains the most widely used animal model for the study of 
PD. Although these models have undoubtedly contributed to a better under-
standing of many features of PD, most studies have focused on the ability of 
these models to induce nigrostriatal pathway damage and motor alterations 
associated with advanced phases of PD. However, until recently, no well-ac-
cepted model of the early phase of PD was available in the literature. The 
present review seeks to document these challenges using our earlier review 
(Da Cunha et al. 2002) as a basis for integrating the subsequent behavioral 
and neurochemical studies showing that the intranigral infusion of MPTP into 
rats causes a partial loss of dopamine neurons in the SNc and depletion of 
striatal dopamine, resulting in sensory and memory defi cits with no major mo-
tor impairments, thus representing a model of the early phase of PD. 
Finally, the fact that most of the drugs currently available for the treatment 
of PD (such as levodopa) are more effi cient in alleviating motor than cogni-
tive impairments has led many researchers to postulate non-dopaminergic 
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mechanisms for the cognitive symptoms of this disease. Here, we will briefl y 
review clinical and non-clinical studies evaluating the potential of caffeine and 
other adenosine receptor antagonists to restore defective learning and mem-
ory processes in PD.
COGNITIVE IMPAIRMENTS IN PARKINSON’S DISEASE
In addition to the characteristic motor symptoms, subtle cognitive impairments 
can be observed even during the early phases of PD (Dubois and Pillon 1997; 
Bosboom et al. 2004). They comprise a dysexecutive syndrome that includes 
attentional and working memory impairments accompanied by secondary 
defi cits in the internal representation of visuospatial stimuli and in the use of 
declarative memory storage (Bradley 1989; Owen et al. 1993; Dubois and Pil-
lon 1997; Tamaru 1997; Bosboom et al. 2004). Skill and habit learning is also 
impaired in these patients (Knowlton et al. 1996). Almost one-third of patients 
may eventually progress to dementia (Aarsland et al. 1996). 
Dysexecutive syndrome represents the core of the cognitive impairments 
and dementia observed in PD, and appears even during early stages of the 
disease (Dubois and Pillon 1997; Tamaru, 1997; Bosboom et al. 2004; Owen 
2004; Zgaljardic et al. 2004). Executive function describes a wide range of 
cognitive functions required for goal-directed, adaptive behavior in response 
to new, challenging environmental situations, including planning, task man-
agement, attention, inhibition, monitoring, and coding. All of these functions 
are attributable to the prefrontal cortex and therefore, PD cognitive disabilities 
resemble cognitive defi cits found in frontal cortex patients (Tamaru 1997; Ma-
rie et al. 1999; Owen 2004). 
A recent positron emission tomography study by Aalto et al. (2005) has 
shown increased dopamine release in the frontal cortex of human subjects 
performing a working memory task. Working memory (Stebbins et al. 1999; 
Marie and Defer 2003), especially spatial working memory (Pillon et al. 1996, 
1997; Owen et al. 1997), fails in non-demented PD patients. The articulatory 
(verbal-phonological) component of the working memory is usually preserved, 
but when a verbal working memory task demands more attention, a defi ciency 
is also observed in these patients (Moreaud et al. 1997; Owen 2004). These 
impairments are possibly the consequence of failure of the central executive 
component that manages the short-term memory. Thus, these impairments 
appear when the working memory tasks present a higher demand on execu-
tive functions such as planning and attention shifting (Bosboom et al. 2004). 
Many studies have tested whether PD patients, who are known to have 
a striatal depletion of dopamine, present non-declarative learning and mem-
ory defi cits (Bondi and Kaszniak 1991). These patients fail to improve mirror 
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reading of words that appeared only once during the test, an impairment at-
tributable to a skill learning defi cit (Thomas et al. 1996; Koenig et al. 1999). 
PD patients have been shown to present impaired skill learning not only for 
visuoperceptual but also for motor skill tasks such as puzzle assembly, press-
ing specifi c keys on a computer keyboard in response to a stimulus present-
ed on the computer screen, and drawing lines in hidden mazes (Bondi and 
Kaszniak 1991; Thomas et al. 1996; Moreaud et al. 1997). Many defi cits of 
PD patients in performing non-declarative tasks relay on the initial learning 
phase (Dujardin and Laurent 2003). On the other hand, there is no consensus 
about whether PD spares declarative memory (Thomas et al. 1996; Bondi and 
Kaszniak 1991). PD patients are generally not impaired to encode and store 
consolidated new information, but they present diffi culties in retrieving this in-
formation, particularly when they have to self-initiate remembering strategies 
(Dujardin and Laurent 2003). A failure in executive functions may explain this 
defi cit. However, the non-intentional and automatic nature of a non-declara-
tive task, such as learning a list of words or matching pairs of words, may also 
determine whether it can be learned normally or not by PD patients (Faglioni 
et al. 1995, 1997; Roncacci et al. 1996). Some authors explain the declara-
tive defi cits reported in some studies involving PD patients as resulting from 
the fact that they require a larger number of repetitions of the task to translate 
non-declarative (procedural) into declarative knowledge (Pascual-Leone et 
al. 1993). 
Habits are by defi nition stimulus-response associations that are uncon-
sciously learned through repetitively rewarded experiences. The main diffi cul-
ty to model a habit task is to guarantee that the subjects will not respond con-
sciously in order to receive the reward. One of the main well-designed studies 
planned to test whether non-demented PD patients are impaired in stimu-
lus-response habit learning used a probabilistic classifi cation task (Knowlton 
et al. 1996). The probabilistic structure of the task permitted the subjects to 
learn the task unconsciously by trial-and-error. PD patients scored worse than 
Alzheimer’s disease patients and healthy subjects, but when asked about 
it, they remembered to have participated in the previous training sessions. 
Alzheimer’s disease patients, on the other hand, learned this task like healthy 
subjects, but barely remembered the training episode. This study supports 
the double dissociation proposed for the medial temporal- and basal ganglia-
mediated declarative (episodic) and non-declarative (implicit habit learning) 
memory systems, respectively (Packard and Knowlton 2002). 
 The risk of developing dementia is up to six times higher in PD pa-
tients than in healthy subjects of the same age (Aarsland et al. 1996). The 
core of the impairments lies in executive functions (e.g. set-shifting) (Girot-
ti 1986). Mood (e.g. depression), and psychotic (e.g. visual hallucinations) 
symptoms are also common in demented PD patients. Other common im-
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pairments include visuospatial and visuoconstructive skills. Speech and lan-
guage diffi culties, such as naming and sentence comprehension, are also 
common. Furthermore, poor verbal fl uency would be predictive of dementia 
in PD. Declarative memory impairments are present, but are less severe, as 
compared to Alzheimer’s disease. There is a defi cit in free recall, but it can be 
compensated for by semantic cueing. Furthermore, PD patients have more 
problems to recall than to encode declarative memories, i.e., their impairment 
relies on diffi culties in activating processes involved in the functional use of 
memory storages, probably as a consequence of the dysexecutive syndrome. 
Recognition memory is relatively intact (Bosboom et al. 2004). Some of these 
cognitive impairments, especially attention impairment, are aggravated by a 
degeneration of cholinergic neurons in the nucleus basalis of Meynert and 
of noradrenaline neurons in the locus ceruleus that also occur in PD. On the 
other hand, impairments in declarative memory, aphasia and apraxia, when 
present, are related to cortical pathology indicative of Alzheimer’s disease or 
Lewy body dementia. Regarding the last co-morbidity, it is noteworthy how 
many characteristics of PD dementia resemble Lewy body dementia. Addi-
tionally, postmortem studies have revealed that many Lewy body disease pa-
tients had been wrongly diagnosed in life as having PD patients and many PD 
patients develop Lewy body disease later on (Zgaljardic et al. 2004). 
THE BASAL GANGLIA SYSTEM OF LEARNING AND MEMORY
As important as knowing the cause of PD is to know the normal function of 
the brain components affected by this disease. Dopamine neurons of the SNc 
modulate the basal ganglia, which are composed of the caudate nucleus and 
putamen (altogether called striatum) and the globus pallidus. Due to their re-
ciprocal connections with these core structures of the basal ganglia, the sub-
stantia nigra, ventral tegmental area and the subthalamic nucleus are con-
sidered to be associated basal ganglia structures (Alexander and Crutcher 
1990). Neurons from all parts of the neocortex project to the striatum. Striatal 
neurons, in turn, project to the globus pallidus or to the substantia nigra pars 
reticulata which projects to the ventrolateral thalamus that, in turn, projects 
back to the frontal cortex (Alexander and Crutcher 1990). Therefore, the ac-
tivity of sensory and motor parts of the cortex affects the activity of the basal 
ganglia that, in turn, modulate the activity of motor and cognitive parts of the 
frontal cortex. The positive modulation exerted by glutamate thalamic neurons 
on the frontal cortex is under inhibitory control of GABAergic neurons of the 
globus pallidus and the substantia nigra pars reticulata. This inhibition can 
be either blocked by a direct pathway or increased by an indirect pathway of 
neurons that arise in the striatum. Midbrain dopamine neurons play a dual 
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role in the modulation of the activity of these striatal neurons. Acting on D1-
like or D2-like dopamine receptors, the dopamine released by these neurons 
activates the direct pathway and inhibits the indirect pathway, respectively. 
Both actions result in a positive modulation of the motor and cognitive func-
tions of the frontal cortex (Alexander et al. 1986). According to this view, it is 
clear that the loss of midbrain dopamine neurons that occurs in PD results in 
the impairment of both motor and cognitive functions. 
How does the decrease of dopamine concentration in the striatum, and 
its consequent decrease in the positive modulation exerted by the basal gan-
glia loop on the frontal cortex, causes the cognitive impairments observed 
in PD? Let us start with motor skills and habit learning. The primary motor 
cortex, supplementary motor area and somatosensory cortex neurons di-
rectly control the fi ring of spinal motor neurons, leading to consciously willed 
movements. Motor programs are the orchestrated sequences of commands 
to functional groups of muscles that govern movements at or around the joints 
(Alexander and Crutcher 1990). Where are these motor programs encoded 
and stored? The striatum is in a strategic position to participate in the encod-
ing of such motor programs that will constitute the framework of the motor 
skills and habits (Packard and Knowlton 2002). The ability to perform a skill 
demands the coordinated activity of muscle groups from different parts of the 
body, the continuous integration of information about the contraction state of 
these muscles, and the visual follow-up of the movement in order to make 
fi ne adjustments for proper movements. Habit learning consists of increasing 
the probability that a sensory stimulus triggers a motor program designed for 
a particular behavioral response (White and McDonald 2002). As mentioned 
above, both sensory and motor regions of the entire cortex project to the 
striatum. The primary motor cortex also presents a somatotopic organization. 
Inputs from regions of the primary motor (MI) and sensory (SI) cortex that rep-
resent the same part of the body send projections to the same region within 
the striatum (Flaherty and Graybiel 1998). However, while the cortical regions 
form a single and continuous representation of the entire body, the represen-
tation of these areas of the body in the striatum is broken into a mosaic and is 
redundant, i.e., each part of the body is represented by multiple striatal units 
called matrisomes. After these somatosensorimotor inputs are processed in 
the striatum, the multiple matrisomes representing the same body parts send 
overlapping projections to the globus pallidus, where a unique and continuous 
representation of the body is restored (Graybiel 1998). Primary cortex regions 
for other sensory modalities, i.e., vision, hearing and smell, also send projec-
tions to the striatum (Calabresi et al. 1996). Notice that the multiple mosaic 
representation of sensory and motor information in the striatum allows the 
association of different stimuli with the activation of movement sequences in-
volving different parts of the body. The capacity of dopamine neurons to either 
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inhibit or stimulate the basal-cortical output and to induce fi ring-dependent 
plasticity in the corticostriatal synapses enables this system to form experi-
ence-driven stimulus-response programs that are the basis of skills and habit 
learning (Graybiel et al. 1994; Graybiel 1998).
Working memory and executive functions, also affected in PD, depend 
on the activity of the prefrontal cortex (Dirnberger et al. 2005). There are 
loops integrating the dorsolateral and the orbitofrontal areas of the prefron-
tal cortex with the basal ganglia (Alexander et al. 1986). A study by Postle 
and D’Esposito (1999) showed increased activity of these cortical regions and 
the dorsal striatum when subjects were performing spatial working memory 
tasks. Furthermore, Lewis et al. (2003) reported that cognitive impairments in 
early PD, including working memory, are accompanied by a reduced activity 
in the frontostriatal neural circuitry. The concept of working memory involves 
the integration and maintenance of information for its prospective use when 
selecting the appropriate behavior (Baddeley 2003). This process could in-
volve the transformation of sensory cues into a code response. The prefrontal 
cortex is at the top hierarchy of the sensory and motor systems (Faw 2003). 
Like the striatum, it can receive information from all sensory modalities and 
control the motor output. While doing this, it works in consonance with basal 
ganglia loops. These corticobasal loops can run parallel subroutines that are 
unconsciously operated, while the prefrontal cortex is involved in solving con-
scious demands for the ongoing behavior. Like the striatum, the prefrontal 
cortex is also modulated by dopamine neurons arising in the midbrain (Costa 
et al. 2003). Therefore, it is easy to understand how the abnormal depletion 
of dopamine levels in these brain regions as observed in PD can affect work-
ing memory. In the same way, attention and other executive functions of the 
prefrontal cortex will be affected by dopamine depletion in the striatum and 
prefrontal cortex (Dubois and Pillon 1997; Owen 2004).
MPTP-LESIONED RAT AS AN ANIMAL MODEL OF COGNITIVE 
IMPAIRMENTS OBSERVED DURING THE EARLY PHASE OF 
PARKINSON’S DISEASE
In the early 1980s, the dopaminergic neurotoxin MPTP was accidentally dis-
covered when a group of young drug addicts in California developed an idio-
pathic parkinsonian syndrome. Investigation revealed that the syndrome was 
caused by self-administration of a “synthetic heroin” analogue that had been 
contaminated with a byproduct (MPTP) during manufacturing (Davis et al. 
1979; Langston et al. 1983). At present, MPTP represents the most important 
and most frequently used neurotoxin applied to animal models of PD, pre-
senting advantages over all other toxic PD models since it causes a specifi c 
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loss of dopamine neurons and induces symptoms identical to PD in humans 
(Przedborski and Vila 2003). 
MPTP is highly lipophilic and readily crosses the blood-brain barrier. It 
is then converted in the glia into its active metabolite, 1-methyl-4-phenyl-
pyridinium cation (MPP+), by monoamine oxidase B, an enzyme involved in 
catecholamine degradation. MPP+ is taken up by the dopamine transporter 
and accumulates in dopamine neurons. Absorbed MPP+ concentrates in mi-
tochondria where it inhibits complex I of the electron transport chain, thereby 
reducing ATP generation and causing the production of reactive oxygen spe-
cies, inducing apoptotic death of dopamine neurons (see Beal 2001).
MPTP can be given in a variety of regimens (e.g. gavage or stereotactic 
injection), but the most common and reproducible form is systemic admin-
istration (e.g. subcutaneous, intravenous, intraperitoneal or intramuscular) 
(Przedborski et al. 2001). In primates such as humans, monkeys and ba-
boons, MPTP causes irreversible and severe parkinsonian symptoms that are 
indistinguishable from those of sporadic PD (Bezard et al. 1997, 2001; Pzed-
borski et al. 2001). In contrast to primates, rodents are less sensitive to MPTP 
toxicity (Schmidt and Ferger 2001). Nevertheless, the C57 black mouse strain 
was found to be sensitive to systemic injection of MPTP and was signifi cantly 
more selective than other mouse strains in terms of affecting mesencephalic 
dopamine neurons (Sedelis et al. 2000, 2001; Schmidt and Ferger 2001). 
Therefore, because of the economical, logistic and ethical constraints related 
to experimental research in primates, the MPTP mouse model has become 
the most commonly used animal model of PD to study neuropathological and 
neurochemical changes (Schmidt and Ferger 2001; Schober 2004). 
On the other hand, few studies have used MPTP-lesioned rats. The main 
reason for this is that shortly after the discovery that MPTP causes a parkin-
sonian syndrome when systemically administered to humans and non-human 
primates (Langston et al. 1983), no susceptibility of rats to MPTP has been 
reported when the drug was administered systemically (Chiueh et al. 1984; 
Kalaria et al. 1987). The conspicuous insensitivity of rats to MPTP toxicity 
may be related to a species-specifi c MPTP metabolism and/or sequestration 
of MPP+, which could be different in rats compared to mice and monkeys (Jo-
hannessen et al. 1985; Kalaria et al. 1987; Schmidt and Ferger 2001). For this 
reason some authors (see Schmidt and Ferger 2001; Schober 2004) did not 
recommend rats for MPTP research. Recently, this view has been re-evalu-
ated following the fi ndings that the infusion of MPTP directly into the rat SNc 
causes a partial loss of dopamine neurons and depletion of striatal dopamine 
that result in sensory and memory defi cits (Harik et al. 1987; Da Cunha et al. 
2001, 2002).
Rats with SNc lesion induced by intracerebral administration of 6-OHDA 
have been successfully used to study the physiology of nigrostriatal pathway 
RMAC_dic_2006.indd   227 21/05/2007   01:30:04 p.m.
228 DA CUNHA, PREDIGER, MIYOSHI AND TAKAHASHI
disruption, and have become a very popular model of motor alterations re-
lated to advanced phases of PD characterized by gross motor alterations (Un-
gerstedt 1968; Shwarting and Huston 1996). However, until recently, no well-
accepted model of the early phase of PD was available in the literature. Such 
model is very important to study the mechanisms of the defi cits characteristic 
of this phase and to screen putative drugs able to improve and maintain the 
quality of life of PD patients during a phase when they can better benefi t from 
treatment and be more effectively cared for.
Since the early phase of PD is characterized by only partial lesion of the 
SNc (less than 70% cell loss), mild motor impairment and cognitive defi cits, we 
have proposed that bilaterally MPTP-lesioned rats represent a good model of 
this early phase of the disease. This model of PD seems to be appropriate for 
this purpose because, in contrast to unilaterally SNc-lesioned rats, animals 
with bilateral lesions do not present gross motor alterations that would other-
wise confound the interpretation of poor scores in memory tasks as indicative 
of cognitive impairment. Extensive tests have shown that 3 weeks after sur-
gery these animals present no signifi cant sensorimotor disturbances. At this 
time, the animals are not aphagic or adipsic and their exploratory behavior 
scored in an open fi eld or in a shuttle-box, as well as their time of permanence 
in a rota-rod, is normal (Da Cunha et al. 2001; Miyoshi et al. 2002). The rea-
son for this lack of motor impairment is probably due to a combination of the 
following factors: 1) the partial nature of the SNc lesion and striatal dopamine 
depletion induced by MPTP, 2) a compensatory neural plasticity in the basal 
ganglia circuit during the 3 weeks after surgery, and 3) the bilateral nature of 
the lesion. 
Since bilateral lesion of the SNc by MPTP does not cause motor impair-
ments in rats, the next step was to study what kinds of memory are affected 
in these animals. Nowadays, it is generally accepted that there are multiple 
memory systems. Two of the most studied examples are the hippocampal 
and the basal ganglia memory systems, which process and store information 
independently and in different styles. According to this view, the hippocampal 
system processes spatial-temporal memories involving relations among en-
vironmental cues (e.g. episodic memory in humans), while the basal ganglia 
system is involved in habit learning in which a single stimulus is repeatedly 
associated with a response (Packard and Knowlton 2002; McDonald et al. 
2004; White 2004). As pointed out above, there is evidence to support the 
idea that PD patients present defi cits to learn habit tasks (Knowlton et al. 
1996; Dubois and Pillon 1997). Other studies consistently reported that PD 
patients are impaired in spatial working memory and other central executive 
functions (Owen et al. 1997; Owen 2004). Our studies using MPTP-induced 
SNc-lesioned rats as a model of PD are consistent with this view. Two differ-
ent versions of the Morris water maze task proved to be particularly suitable 
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to test spatial memory or habit learning. In the spatial version, rats learn to 
escape to a submersed platform that is maintained in the same location in the 
water maze from the beginning to the end of the experiment. In this case, the 
animals need to make associations among the spatial environmental cues in 
order to form a cognitive map that helps them to fi nd the platform (Morris et 
al. 1982). In the habit version, the animals learn to associate the position of a 
white ball attached to the platform and protruding above the water. The posi-
tion of the platform is changed randomly among trials. In this case, a single 
stimulus (the ball) is repeatedly associated with a response of approaching the 
platform. Spatial memory critically depends on the integrity of the hippocam-
pus but not of the dorsal striatum, whereas habit learning critically depends on 
the integrity of the dorsal striatum but not of the hippocampus (Packard and 
McGaugh 1992; White and McDonald 2002). 
Studies from our laboratory have shown that SNc lesion does not affect 
learning or memory in the spatial version of the water maze, but hippocampal 
inactivation with lidocaine prevents animals from fi nding the submersed plat-
form. An opposite response was observed with the cued version, since SNc 
lesion, but not hippocampal inactivation, impairs learning and memory. No 
signifi cant interaction was observed between the SNc lesion and hippocam-
pal inactivation conditions in terms of affecting scores in the spatial or in the 
cued version of the water maze (Miyoshi et al. 2002; Da Cunha et al. 2002). 
These results suggest that the nigrostriatal pathway is an essential part of 
the basal ganglia memory system which processes stimulus-response habit 
learning and works independently of the hippocampal memory system which 
processes spatial/relational memories. 
MPTP rats also presented a defi cit in the working memory version of the 
Morris water maze (Miyoshi et al. 2002). In this version, the position of the 
platform is maintained constant during four subsequent trials performed on 
the same day, but its position is changed on each subsequent training day. 
With this protocol, the animal cannot use the previous day reference memory 
to fi nd the platform and, thus, has to use its working memory of the previous 
trial to fi nd it. Another rat learning and memory task affected by bilateral le-
sion of the SNc is two-way active avoidance (Da Cunha et al. 2001). This task 
models multiple kinds of memory, but habit learning is an important compo-
nent of this task, in which a single cue (a sound signal) is repeatedly associ-
ated with a foot shock that can be avoided by crossing to the opposite side 
of a shuttle box. The impairing effect of nonspecifi c (electrolytic) SNc lesion 
on this task has been previously reported by Mitcham and Thomas (1972). 
The dependency to learn this task on the integrity of the dorsal striatum has 
also been reported in other studies (Kirkby and Polgar 1974; El Massioui and 
Delatour 1997).
The defi cit of MPTP rats has also been observed in another working 
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memory task named delayed alternation in a Y-maze (Braga et al. 2005). In 
this task, the rats have to alternate between two arms of a Y-maze in order to 
fi nd a food pellet. During the 20-s intertrial intervals the animals have to main-
tain in their working memory which arm they had previously visited in order to 
alternate correctly. SNc lesion with MPTP increased the number of errors in 
both pretrained and naive rats. In another study, we have shown that the left 
SNc seemed to be more critical than the right SNc for the performance of the 
working memory of rats in a version of the Morris water maze (Bellissimo et 
al. 2004).
EFFECTS OF DOPAMINERGIC DRUGS ON THE MPTP RAT MODEL OF 
MEMORY IMPAIRMENTS RELATED TO PD
Controversy exists regarding the dopaminergic nature of the cognitive impair-
ments in PD. Since neurons producing other neurotransmitters (e.g. acetyl-
choline, serotonin, noradrenaline) are also reported to degenerate in this dis-
ease (Braak et al. 2003), some authors consider that they may cause some 
cognitive and behavioral dysfunction, especially in demented patients (Dujar-
din and Laurent 2003; Zgaljardic et al. 2004). On the other hand, other inves-
tigators have reported a correlation between the loss of dopamine neurons of 
the nigrostriatal pathway and the degree of dementia (Rinne et al. 1999) and 
performance in neuropsychological tests in PD patients (Marie et al. 1999; 
Bruck et al. 2001). Animal models can contribute to establish the specifi c im-
plications of each neurotransmitter system in the cognitive impairments of 
PD. The role of dopamine can be studied by using models that are specifi c 
for dopamine depletion, such as the MPTP models, and by investigating the 
effects of dopamine receptor antagonists on cognition.
Ogren and Archer (1994) reported that haloperidol and other dopamine 
receptor antagonists impair acquisition and retention in the two-way active 
avoidance task, indicating that the performance of this task depends on nor-
mal dopaminergic neurotransmission. The sensitivity of this task to SNc le-
sions and striatal dopamine manipulations and the facility to perform this task 
– only two sessions are necessary in an automated apparatus – make it par-
ticularly suitable to test drugs with a potential to treat the cognitive symptoms 
of PD. Thus, we tested the effect of the most effi cient drug used in the treat-
ment of the motor symptoms of PD, levodopa, on SNc-lesioned rats. The 
administration of benserazide/levodopa to MPTP-lesioned rats, at a dose that 
restores the striatal level of dopamine, did not reverse the MPTP-induced 
learning and memory impairment (Gevaerd et al. 2001a). 
In humans, the benefi cial effect of levodopa on improving the cognitive 
function affected in PD is controversial. While some studies indicate an im-
RMAC_dic_2006.indd   230 21/05/2007   01:30:05 p.m.
231A RAT MODEL OF THE COGNITIVE IMPAIRMENTS IN PARKINSON’S DISEASE
provement of cognitive functions in PD patients treated with levodopa (Beard-
sley and Puletti 1971; Loranger et al. 1972; Girotti et al. 1986; Cooper et al. 
1992; Cools et al. 2001), others have shown that this treatment may cause no 
or only mild improvement (Pillon et al. 1989; Growdon et al. 1998; Rektorova 
et al. 2005), or may even aggravate PD cognitive impairments (Huber et al. 
1989; Poewe et al. 1991; Prasher and Findley 1991; Cools et al. 2001). Go-
tham et al. (1988) proposed that the detrimental effects of levodopa observed 
in some cognitive tasks may be due to excessively high concentrations of 
dopamine in areas such as the prefrontal cortex where dopamine depletion 
is less severe. We showed that this was the case for MPTP rats treated with 
levodopa (Gevaerd et al. 2001a). The levodopa dose necessary to restore a 
normal striatal level of dopamine caused a large increase of dopamine levels 
in extrastriatal brain regions. Therefore, that study proves that, at least for 
the MPTP rat model of PD, levodopa therapy is not effective in improving 
the observed memory impairment because it appears to tilt the balance be-
tween dopamine levels in the striatum and in extrastriatal regions such as the 
prefrontal cortex (and also limbic structures), resulting in a cognitive defi cit. 
In accordance with this idea, a recent work by Bruck et al. (2005) showed 
that the fi nding of early phase PD patients scoring poorly in tests measuring 
frontal lobe functions was positively correlated with increased cortical Fdopa 
uptake. 
Furthermore, the various cognitive impairments of PD may depend on 
different brain areas that are differently depleted of dopamine, such as the 
dorsal striatum and prefrontal cortex. A study by Swainson et al. (2000) has 
shown that non-medicated PD patients performed better than medicated pa-
tients in a reversal test that depends on the striatum and ventral frontal cortex. 
However, the same patients performed worse than medicated patients in a 
spatial recognition memory task that depends on the dorsolateral frontal cor-
tex. The authors suggested that the levodopa treatment overdosed the dorso-
lateral frontal cortex, which was less affected by the disease, at the same time 
that it restored a normal level of dopamine in the striatum and ventral frontal 
cortex. Cools et al. (2001) reported similar results showing that levodopa-
treated patients can perform better or worse in tasks depending on different 
components of the frontostriatal circuitry. In that study, levodopa withdrawal 
improved performance in probabilistic reversal learning, a task that depends 
on the orbitofrontal cortex, ventral frontal cortex, and ventral striatum. How-
ever, levodopa withdrawal impaired performance in a set-shifting task, which 
depends on the dorsolateral frontal cortex and dorsal caudate nucleus. 
Therefore, although the above studies discourage the use of levodopa 
therapy to treat some PD cognitive symptoms, it does not imply that these 
cognitive symptoms are not related to the degeneration of the nigrostriatal 
pathway. In addition to the observed impairment in two-way active avoid-
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ance learning caused by the depletion of striatal dopamine in MPTP-lesioned 
rats, other important fi ndings suggest that mnemonic processes depend on 
a normal level of stimulation of the striatal dopamine receptors. Packard and 
White (1991) and Packard and McGaugh (1994) showed improved cognitive 
performance after intrastriatal administration of a D2 receptor agonist to rats. 
Also, Schneider et al. (1994) observed a cognitive improving effect of the 
systemic administration of a D1-receptor agonist to MPTP-lesioned monkeys. 
D1-receptor agonists have also been reported to release acetylcholine in the 
frontal cortex and dorsal striatum and to improve cognitive performance in 
rats (Steele et al. 1997). More recently, other authors have suggested that D1 
receptor agonists can be useful in the treatment of cognitive impairments of 
PD (Nichols and Lewis 2004; Salmi et al. 2004), and it would be interesting to 
test them in an animal model such as the MPTP rat model used here.
The failure of levodopa to reverse the memory impairment of MPTP rats 
in the two-way active avoidance task is likely to be related, at least in part, 
to the failure of this treatment to improve the cognitive impairments of PD 
patients, as mentioned above. Since this was equally observed in some clini-
cal studies and in our rat model of memory impairments related to PD, these 
results encouraged the use of the rat MPTP model in studies on alternative 
drug therapies for the treatment of the cognitive impairments of PD. 
EFFECTS OF ADENOSINE RECEPTOR ANTAGONISTS ON THE MPTP 
RAT MODEL OF MEMORY IMPAIRMENTS RELATED TO PD
It is well known that adenosine receptors are densely expressed in the striatum 
and exert a modulatory infl uence on dopamine neurotransmission (Moreau 
and Huber 1999; Svenningsson et al. 1999). The understanding of the role of 
adenosine in basal ganglia and its anatomical and functional relationship with 
the striatal dopamine D1 and D2 receptors has increased over the last years, 
providing evidence of an antagonistic interaction between A(2A)/D2 and A(1)/
D1 receptors in the striatum (Fuxe et al. 1998; Franco et al. 2000). Moreover, 
neuroprotective properties of caffeine and A(2A) adenosine receptor antago-
nists have been reported for dopamine neurons in the SNc (Chen et al. 2001). 
Furthermore, adenosine receptor-related drugs seem to be promising candi-
dates for the symptomatic treatment of PD, since there is evidence that caf-
feine directly increases dopamine release from striatal nerve terminals (Okada 
1997). This dopamine-releasing effect of caffeine was also observed with the 
A(2A) adenosine receptor antagonist, ZM 241385, in striatal synaptosomes 
(Da Cunha et al. 2002). All these putative anti-Parkinson effects may explain 
the fi nding that the risk of PD is signifi cantly reduced among coffee drinkers 
(Paganini-Hill 2001). Based on these promising effects, adenosine receptor 
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antagonists are being pursued as putative drugs to treat PD (Ferre et al. 2001; 
Wardas 2001).
Caffeine has also been reported to improve learning and memory in a 
variety of animal (Pare 1961; Molinengo et al. 1995; Cestari and Castellano 
1996; Howell et al. 1997) and human studies (Riedel et al. 1995; Pollina and 
Calev 1997). In our laboratory we also demonstrated that pretraining and pre-
test systemic administration of caffeine can improve the memory of rats in 
various tasks (Angelucci et al. 1999, 2002; Prediger and Takahashi 2005; Pre-
diger et al. 2005a,b,c). Due to the failure of levodopa to reverse the memory 
impairments caused by SNc lesion in rats, we decided to test whether caffeine 
is effective to do so. Caffeine (0.1 to 0.3 mg/kg, i.p.) reverses the impairing 
effect of the MPTP-induced SNc lesion of rats on the avoidance scores in the 
training and test sessions of a two-way active avoidance task (Gevaerd et al., 
2001b). This result suggests that the effects of caffeine and other adenosine 
receptor antagonists acting on the striatal dopaminergic system can be useful 
to restore defective learning and memory processes in PD.
CONCLUDING REMARKS
The data reviewed here indicate the successful refi nement of an experimental 
model of PD, and describe behavioral tests that can be used in rodents to study 
early PD-related cognitive defi cits. Because an animal model cannot provide the 
full range of effects of such complex human neurodegenerative disease, a ro-
dent model by injecting MPTP into the SNc was constructed by drawing from 
various sources, which included tests of spatial memory, working memory and 
habit learning. Measures of cognitive impairments in the absence of compromis-
ing sensory and/or motor disabilities have been obtained and tentatively related 
to current theoretical constructs of human cognition. The studies reviewed here 
stress the critical role of the dopaminergic nigrostriatal pathway as an essential 
element of the basal ganglia neural circuit, participating in specifi c learning and 
memory processes in the brain. The proposed MPTP rat model of PD-related 
memory impairments proved to be appropriate for studies of the neural circuits 
supporting this cognitive pathology. Moreover, our studies consistently suggest 
that adenosine receptor antagonists (e.g. caffeine), previously reported as puta-
tive drugs for treating the motor symptoms of PD, are also promising drugs to 
treat the cognitive impairments related to this disease. Considering the failure of 
levodopa to treat these cognitive disabilities, the development of a new class of 
drugs for incorporation into the pharmacological options for the treatment of PD 
is noteworthy. Certainly, additional studies are necessary to better understand the 
neurobiological substrates of early cognitive impairment in PD, as well as the de-
velopment of novel therapeutic strategies for this neurodegenerative disorder.
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